PT - JOURNAL ARTICLE AU - Yuan-Ting Chang AU - Patrick K.A. Kearns AU - Alan Carson AU - David C. Gillespie AU - Rozanna Meijboom AU - Agniete Kampaite AU - Maria del C. Valdés Hernández AU - Christine Weaver AU - Amy Stenson AU - Niall MacDougall AU - Jonathan O’Riordan AU - Margaret Ann Macleod AU - Francisco Javier Carod-Artal AU - Peter Connick AU - Adam D. Waldman AU - Siddharthan Chandran AU - Peter Foley TI - Data-driven analysis shows robust links between fatigue and depression in early multiple sclerosis AID - 10.1101/2022.01.13.22269128 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.13.22269128 4099 - http://medrxiv.org/content/early/2022/01/13/2022.01.13.22269128.short 4100 - http://medrxiv.org/content/early/2022/01/13/2022.01.13.22269128.full AB - Fatigue is common and disabling in multiple sclerosis, yet its mechanisms are poorly understood. In particular, overlap in measures of fatigue and depression complicates interpretation. A clearer understanding of relationships between fatigue and key clinical, neuropsychiatric and imaging variables including depression could yield clinically relevant mechanistic insight. We applied a data-driven multivariate network approach to quantify relationships between fatigue and other variables in early multiple sclerosis.Data were collected from Scottish patients with newly diagnosed, immunotherapy-naïve, relapsing-remitting multiple sclerosis at baseline and month 12 follow-up in FutureMS, a nationally representative multicentre cohort. Subjective fatigue was assessed using the validated Fatigue Severity Scale. Detailed phenotyping included measures assessing physical disability, affective disorders, objective cognitive performance, subjective sleep quality, and structural brain imaging. Bivariate correlations between fatigue and other variables were calculated. Network analysis was then conducted to estimate partial correlations between variables, after accounting for all other included variables. Secondary networks included individual depressive symptoms, to control for overlapping symptom items in measures of fatigue and depression.Data from 322 participants at baseline, and 323 at month 12, were included. At baseline, 49.5% of the cohort reported clinically significant fatigue. Bivariate correlations confirmed that fatigue severity was significantly correlated with all included measures of physical disability, affective disturbance (anxiety and depression), cognitive performance (processing speed and memory/attention), and sleep quality, but not with structural brain imaging variables including normalized lesion and grey matter volumes. In the network analysis, fatigue showed strong correlations with depression, followed by Expanded Disability Status Scale. Weak connections with walking speed, subjective sleep quality and anxiety were identified. After separately controlling for measurement of “tiredness” in our measure of depression, some key depressive symptoms (anhedonia, subjective concentration deficits, subjectively altered speed of movement, and appetite) remained linked to fatigue. Conversely, fatigue was not linked to objective cognitive performance, white matter lesion volume, or grey matter volumes (cortical, subcortical or thalamic). Results were consistent at baseline and month 12. Depression was identified as the most central variable in the networks. Correlation stability coefficients and bootstrapped confidence intervals of the edge weights supported stability of the estimated networks.Our findings support robust links between subjective fatigue and depression in early relapsing-remitting multiple sclerosis, despite absence of links between fatigue and either objective cognitive performance, or structural brain imaging variables. Depression, including specific depressive symptoms, could be a key target of treatment and research in multiple sclerosis-related fatigue.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFutureMS has been funded by a grant from the Scottish Funding Council to Precision Medicine Scotland Innovation Centre (PMS IC) and Biogen Idec Ltd Insurance. Insurance provided by the Co-Sponsors: NHS Lothian and the University of Edinburgh. PK is funded by an ECAT/Wellcome PhD Studentship. YTC, PK, and PF have received funding from Rowling Scholar Fellowship Fund of the Anne Rowling Regenerative Neurology Clinic. Additional funding for authors came from the MS Society Edinburgh Centre for MS Research (grant reference 133; RM, AK). MVH is funded by the Row Fogo Charitable Trust (grant no. BRO-D.FID3668413). Funds by the Wellcome Trust (104916/Z/14/Z), Dunhill Trust (R380R/1114), Edinburgh and Lothians Health Foundation (2012/17), Muir Maxwell Research Fund and the University of Edinburgh towards the 3T scanner at Edinburgh site are also gratefully acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained prior to study entry according to the Declaration of Helsinki and ethical approval was granted by the South East Scotland Research Ethics Committee 02 (Reference: 15/SS/0233).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThird party data requests will be handled on a case by case basis by the FutureMS steering committee and data custodians as per the approval guidance of the Research Ethics Committee.9-HPTNine Hole Peg TestBGbasal ganglia volumeBMIBody Mass IndexCIconfidence intervalDMDsDisease Modifying DrugsDSM-5Diagnostic and Statistical Manual of Mental Disorders, fifth editionEDSSExpanded Disability Status ScaleFSSFatigue Severity ScaleGAD7Generalized Anxiety Disorder-7cGMcortical grey matter volumePASATPaced Auditory Serial Addition TestPHQ-9Patient Heath Questionnaire-9pwMSpeople with MSRRMSrelapsing-remitting multiple sclerosisSDMTSymbol Digit Modality TestSLEEPMultiple Sclerosis Impact Scale-problems sleepingT25FWTimed 25 Foot Walk testTHALAthalamus volumeWMHWhole-brain white matter hyperintensity volume